🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Quiet XR 300mg Tablet contains Quetiapine, an atypical antipsychotic, used to treat:
Avoid consumption of alcohol while taking Quiet XR 300mg Tablet, as it may increase the risk of dizziness or sleepiness.
Quiet XR 300mg Tablet is not recommended for use in pregnant women unless specifically directed by your doctor. If you are pregnant, think you may be pregnant or are planning to become pregnant, consult your doctor before taking this medication.
Quiet XR 300mg Tablet is not recommended for use in breastfeeding women. Therefore, it is important to consult your doctor before taking this medication if you are nursing.
Do not drive or operate any machinery if you feel dizzy or sleepy after taking Quiet XR 300mg Tablet. This medication can impair your ability to perform tasks that require alertness.
Quiet XR 300mg Tablet should be used with caution in patients experiencing urinary retention (difficulty in completely emptying the bladder). Therefore, it is crucial to consult your doctor before taking this medication if you have kidney issues.
Quiet XR 300mg Tablet should be used with caution in patients with liver problems. It is essential to consult your doctor before starting this medication if you have liver conditions.
It acts by blocking certain receptors (dopamine (D2), serotonin 2A (5HT2A)) in the brain that cause abnormal mood changes and mental problems. As a result, it improves the positive and negative symptoms of schizophrenia and bipolar disorder.
Quiet XR 300mg Tablet is used to manage bipolar disorder, schizophrenia, and depression (major depressive disorder). Bipolar disorder (also known as manic depression) is a mental disorder characterized by alternative episodes of mania (sudden unusual extreme sense of happiness) and depression.
Chemical Class:
Receptor Antagonism:
Lack of Affinity:
Proposed Mechanism of Action:
Side Effects Explained by Receptor Antagonism:
Immediate Release:
- Day 1: 50 mg/day PO divided q12hr
- Days 2-3: Increase daily by 25-50 mg q8-12hr to 300-400 mg by Day 4
- Further Adjustments: Increments of 25-50 mg q12hr at intervals >2 days
- Dosage Range: 150-750 mg/day
Extended Release:
- Day 1: 300 mg/day PO
- Subsequent Increases: Up to 300 mg/day at intervals >1 day
- Maintenance (monotherapy): 400-800 mg/day
- Reinitiation:
- If discontinued >1 week: Retitrate dose
- If discontinued <1 week: Reinitiate at previous maintenance dose
Immediate Release (Monotherapy or Adjunct to Lithium/Divalproex):
- Day 1: 100 mg/day PO divided q12hr
- Day 2: 200 mg/day PO divided q12hr
- Day 3: 300 mg/day PO divided q12hr
- Day 4: 400 mg/day PO divided q12hr
- Further Adjustments: Up to 800 mg/day by Day 6 in increments <200 mg/day
- Dosage Range: 400-800 mg/day (max 800 mg/day)
Extended Release:
- Day 1: 300 mg PO once daily
- Day 2: 600 mg PO once daily
- Maintenance (Day 3 onward): 400-800 mg/day PO
Immediate Release or Extended Release:
- Day 1: 50 mg PO at bedtime
- Day 2: 100 mg PO at bedtime
- Day 3: 200 mg PO at bedtime
- Maintenance (Day 4 onward): 300 mg PO at bedtime
Immediate Release:
- Dosage Range: 400-800 mg/day PO divided q12hr
Extended Release:
- Dosage Range: 400-800 mg/day PO in a single dose
Extended Release (Adjunct to Antidepressants):
- Days 1 and 2: 50 mg PO in the evening
- Day 3: May increase to 150 mg PO in the evening
- Dosage Range: 150-300 mg/day
Elderly:
- The slower rate of dose titration and lower daily therapeutic dose are recommended.
Hepatic Impairment:
- Initial dose: 25 mg daily
- Increase in increments of 25-50 mg daily until effective dose according to response and tolerability.
Schizophrenia:
Immediate Release:
- Day 1: 50 mg/day PO divided q12hr
- Days 2-3: Increase daily by 25-50 mg q8-12hr to 300-400 mg by Day 4
- Further Adjustments: Increments of 25-50 mg q12hr at intervals >2 days
- Dosage Range: 150-750 mg/day
Extended Release:
- Day 1: 300 mg/day PO
- Subsequent Increases: Up to 300 mg/day at intervals >1 day
- Maintenance (monotherapy): 400-800 mg/day
- Reinitiation:
- If discontinued >1 week: Retitrate dose
- If discontinued <1 week: Reinitiate at previous maintenance dose
Bipolar I Disorder (Mania):
Immediate Release (Monotherapy or Adjunct to Lithium/Divalproex):
- Day 1: 100 mg/day PO divided q12hr
- Day 2: 200 mg/day PO divided q12hr
- Day 3: 300 mg/day PO divided q12hr
- Day 4: 400 mg/day PO divided q12hr
- Further Adjustments: Up to 800 mg/day by Day 6 in increments <200 mg/day
- Dosage Range: 400-800 mg/day (max 800 mg/day)
Extended Release:
- Day 1: 300 mg PO once daily
- Day 2: 600 mg PO once daily
- Maintenance (Day 3 onward): 400-800 mg/day PO
Bipolar Disorder (Depressive Episodes):
- Day 1: 50 mg PO at bedtime
- Day 2: 100 mg PO at bedtime
- Day 3: 200 mg PO at bedtime
- Maintenance (Day 4 onward): 300 mg PO at bedtime
Bipolar I Disorder (Maintenance):
Immediate Release:
- Dosage Range: 400-800 mg/day PO divided q12hr
Extended Release:
- Dosage Range: 400-800 mg/day PO in a single dose
Administration: This can be taken with or without food. It is advised to take it at the same time each day to maintain consistent medication levels in the body.
- Missed Dose: If you miss a dose, take it as soon as you remember. However, if it is close to the time of your next dose, skip the missed dose and resume your usual dosing schedule.
- Discontinuation: Do not stop taking Quiet XR 300 suddenly without consulting your doctor, as it may worsen your symptoms.
Increased Risk of Drowsiness and Postural Hypotension:
Interaction with CYP3A4 Enzyme:
Recommendations
Avoid taking Quetiapine if you are allergic to it. Seek immediate medical attention if you notice any symptoms such as skin rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, breathing difficulty, etc.
The safety and efficacy of Quetiapine during human pregnancy have not been established. Therefore, Quetiapine should only be used during pregnancy if the benefits justify the potential risks and the administered dose and duration of treatment should be as low and as short as possible. The degree to which Quetiapine is excreted into human milk is unknown. Women who are breast-feeding should therefore be advised to avoid breast-feeding while taking Quetiapine.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.